Kurzfassung

 A 52-week, two arm, randomized, open-label, multicenter study assessing
the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled neovascular agerelated macular degeneration (FALCON)